Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A synthetic 26-residue peptidomimetic conjugate of a cysteine-flanked homing nonapeptide and a D-amino acid amphipathic heptapeptide repeat domain.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (peptidomimetic)
Molecular formula
C₁₁₁H₂₀₆N₃₆O₂₈S₂
Molecular weight
2557.2 g/mol
CAS number
859216-15-2
Amino acids
26
Sequence
CKGGRAKDC-GG-D(KLAKLAK)₂
Modification
Contains two D-enantiomeric (D-amino acid) heptapeptide repeats forming an amphipathic proapoptotic domain; cysteine residues present in the homing motif; linear conjugate connected by a GG linker.
Adipotide is a two-module synthetic peptidomimetic conjugate. The N-terminal CKGGRAKDC homing segment is a cysteine-flanked nonapeptide whose paired cysteine residues constrain the loop conformation. A GG dipeptide linker connects it to the C-terminal D(KLAKLAK)₂ domain, a tandem heptapeptide repeat built entirely from D-enantiomeric amino acids that folds into an amphipathic α-helix. Structural studies of the conjugate have characterized the sequence alignment of the CKGGRAKDC motif and the membrane-associating behavior of the amphipathic helical domain in vitro.
Lyophilized
Store dry at −20 °C or below, protected from moisture and light.
Aliquot to avoid repeated freeze-thaw cycles; protect from light and heat.
Reviews
Daquinag A.C., Zhang Y., Kolonin M.G. (2011). Trends Pharmacol Sci
Ande S.R., Nguyen K.H., Nyomba B.L.G., Mishra S. (2016). Trends Endocrinol Metab
Sibuyi N.R.S., Meyer M., Onani M.O., Skepu A., Madiehe A.M. (2018). Int J Nanomedicine
Reviews
Xu Y.X.Z., Bassi G., Mishra S. (2019). Biol Sex Differ
Fang Y., Kaszuba T., Imoukhuede P.I. (2020). Front Physiol
Cao Y. (2010). Nat Rev Drug Discov
Clinical
ClinicalTrials.gov (2012). ClinicalTrials.gov
Primary research
Salameh A., Daquinag A.C., Staquicini D.I., An Z., Hajjar K.A., Pasqualini R., Arap W., Kolonin M.G. (2016). JCI Insight
Staquicini F.I., Cardó-Vila M., Kolonin M.G., Treplev M., et al. (2011). PNAS
Barnhart K.F., Christianson D.R., Wetterau L., Erickson J.A., et al. (2011). Sci Transl Med
Kim D.-H., Woods S.C., Seeley R.J. (2010). Diabetes
Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. (2004). Nat Med
Kim D.-H., Sartor M.A., Bain J.R., Sandoval D., et al. (2012). Diabetes
Daquinag A.C., Tseng C., Salameh A., Zhang Y., et al. (2015). Cell Death Differ
Daquinag A.C., Tseng C., Zhang Y., Amaya-Manzanares F., et al. (2016). Mol Ther
Gao Z., Daquinag A.C., Yu Y., Kolonin M.G. (2022). Diabetes
Hossen M.N., Kajimoto K., Akita H., Hyodo M., Harashima H. (2012). J Control Release
Bacher S., Achatz G., Schmitz M.L., Lamers M.C. (2002). Biochimie
Bahmani T., Sharifzadeh S., Tamaddon G., et al. (2021). J Biomed Phys Eng
Su F., Ahn S., Saha A., DiGiovanni J., Kolonin M.G. (2019). Oncogene
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| AdipotideThis page | Synthetic peptide (peptidomimetic) | 2557.2 g/mol | 859216-15-2 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods